---
title: "Caris Life Sciences, Inc. (CAI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CAI.US.md"
symbol: "CAI.US"
name: "Caris Life Sciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T22:20:39.975Z"
locales:
  - [en](https://longbridge.com/en/quote/CAI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CAI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CAI.US.md)
---

# Caris Life Sciences, Inc. (CAI.US)

## Company Overview

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.carislifesciences.com](https://www.carislifesciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: B (0.27)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 25 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 100.51% |  |
| Net Profit YoY | -10.85% |  |
| P/B Ratio | 7.13 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4228903197.20 |  |
| Revenue | 907292000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 41.01% | A |
| Profit Margin | 3.75% | C |
| Gross Margin | 65.39% | A |
| Revenue YoY | 100.51% | A |
| Net Profit YoY | -10.85% | D |
| Total Assets YoY | 298.65% | A |
| Net Assets YoY | 267.77% | A |
| Cash Flow Margin | -35.82% | E |
| OCF YoY | 100.51% | A |
| Turnover | 1.25 | A |
| Gearing Ratio | 48.94% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Caris Life Sciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "100.51%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.85%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.13",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4228903197.20",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "907292000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "41.01%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "3.75%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "65.39%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "100.51%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.85%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "298.65%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "267.77%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-35.82%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "100.51%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.25",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "48.94%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.28 | 458/386 | - | - | - |
| PB | 7.13 | 373/386 | 19.36 | 15.21 | 9.43 |
| PS (TTM) | 4.66 | 101/386 | 17.22 | 11.82 | 6.94 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 77% |
| Overweight | 1 | 8% |
| Hold | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.70 |
| Highest Target | 36.00 |
| Lowest Target | 21.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CAI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CAI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CAI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CAI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**